
ALT For over 7 years, NurOwn has shown efficacy on some people with ALS. It worked with one dose in the Phase 2 trial in 2015, again with 3 doses in the Phase 3 trial in 2017-2019, again with 7 doses for a Navy pilot via Right to Try, and finally again with 6 more doses for people who received it via Expanded Access. ALS is a vastly heterogeneous disease. NurOwn worked on some. Some is Enough for approval in a 100% fatal & paralyzing disease. NurOwn had a clinically meaningful & statistically significant impact on people with scores of 27+ on the 48-point functional rating scale. We would never tolerate the FDA failing to approve a cancer therapy because it only worked on early stage cancer. We cannot allow the same fatal logic in ALS. And NurOwn also showed a biological impact across the disease spectrum. These types of biomarkers are used to approve cancer therapies via Accelerated Approval. The FDA must treat ALS therapies with the same equity & urgency.

















